Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Apixaban (1) ·
Asenapine (1) ·
Brivaracetam (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Chlorpromazine (1) ·
Clobazam (1) ·
Clozapine (1) ·
Droperidol (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fluphenazine (1) ·
Fosphenytoin (1) ·
Iloperidone (1) ·
Lacosamide (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Molindone (1) ·
Paliperidone (1) ·
Perampanel (1) ·
Perphenazine (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Pimozide (1) ·
Rivaroxaban (1) ·
Rufinamide (1) ·
Stiripentol (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tiagabine (1) ·
Trifluoperazine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Warfarin (1) ·
Ziprasidone (1) ·
Zonisamide (1)
brand:
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Clozaril (1) ·
Coumadin (discontinued in US but name in common use), Jantoven (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Eliquis (1) ·
Epidiolex (1) ·
Fanapt (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Luminal (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Onfi (1) ·
Orap (1) ·
Prolixin (1) ·
Sabril (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vimpat (1) ·
Xarelto (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
AMPA receptor antagonist (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Phenothiazine D2 antagonist (4) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)
uses:
None (35) ·
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1) ·
'"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"' (1)
starting dose:
None (35) ·
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) ·
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (35) ·
~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)
pregnancy:
Showing below up to 38 results in range #1 to #38.